[S03AA02, tetracycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Tetracycline.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Vitamin A is combined with Tretinoin.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Vitamin A.]
[D05BB02, acitretin, The risk or severity of adverse effects can be increased when Vitamin A is combined with Acitretin.]
[J01AA13, eravacycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Eravacycline.]
[J01AA14, sarecycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Sarecycline.]
[J01AA15, omadacycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Omadacycline.]
[J01AA11, clomocycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Clomocycline.]
[G03DB05, demegestone, The therapeutic efficacy of Demegestone can be decreased when used in combination with Vitamin A.]
[G03AC09, desogestrel, The therapeutic efficacy of Desogestrel can be decreased when used in combination with Vitamin A.]
[G03DB08, dienogest, The therapeutic efficacy of Dienogest can be decreased when used in combination with Vitamin A.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Vitamin A is combined with Bexarotene.]
[M09AX11, palovarotene, The risk or severity of adverse effects can be increased when Vitamin A is combined with Palovarotene.]
[J01AA01, demeclocycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Demeclocycline.]
[L02AA01, diethylstilbestrol, The therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Vitamin A.]
[J01AA02, doxycycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Doxycycline.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Vitamin A resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01AA12, tigecycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Tigecycline.]
[G03CA03, estradiol, The therapeutic efficacy of Estradiol can be decreased when used in combination with Vitamin A.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Vitamin A.]
[D05BB01, etretinate, The risk or severity of adverse effects can be increased when Vitamin A is combined with Etretinate.]
[G03XA02, gestrinone, The therapeutic efficacy of Gestrinone can be decreased when used in combination with Vitamin A.]
[D10BA01, isotretinoin, The risk or severity of adverse effects can be increased when Vitamin A is combined with Isotretinoin.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Vitamin A.]
[J01AA04, lymecycline, The risk or severity of pseudotumor cerebri can be increased when Lymecycline is combined with Vitamin A.]
[G03DC03, lynestrenol, The therapeutic efficacy of Lynestrenol can be decreased when used in combination with Vitamin A.]
[J01AA05, methacycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Metacycline.]
[L04AX03, methotrexate, The risk or severity of adverse effects can be increased when Methotrexate is combined with Vitamin A.]
[J01AA08, minocycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Minocycline.]
[G03DC02, norethindrone, The therapeutic efficacy of Norethisterone can be decreased when used in combination with Vitamin A.]
[G03AC07, norgestrienone, The therapeutic efficacy of Norgestrienone can be decreased when used in combination with Vitamin A.]
[S01GA04, oxymetazoline, The absorption of Vitamin A can be decreased when combined with Oxymetazoline.]
[S01AA04, oxytetracycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Oxytetracycline.]
[G03DB06, chlormadinone, The therapeutic efficacy of Chlormadinone can be decreased when used in combination with Vitamin A.]
[L01XF02, alitretinoin, The risk or severity of adverse effects can be increased when Vitamin A is combined with Alitretinoin.]
[D05AX05, tazarotene, The risk or severity of adverse effects can be increased when Vitamin A is combined with Tazarotene.]
[J01AA09, rolitetracycline, The risk or severity of pseudotumor cerebri can be increased when Vitamin A is combined with Rolitetracycline.]
[N03AG01, valproic acid, Valproic acid may increase the Pseudotumor Cerebri activities of Vitamin A.]
